Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Don M. Bailey unloaded 40,000 shares of Questcor Pharmaceuticals stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $95.54, for a total transaction of $3,821,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on QCOR. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 1st. They now have a $97.00 price target on the stock. Separately, analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Finally, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $86.20.

Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) traded down 1.11% during mid-day trading on Wednesday, hitting $94.73. 1,120,054 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 1-year low of $45.41 and a 1-year high of $97.80. The stock’s 50-day moving average is $91.28 and its 200-day moving average is $75.98. The company has a market cap of $5.602 billion and a price-to-earnings ratio of 18.09. Questcor Pharmaceuticals also was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 17,989,114 shares, a decrease of 6.5% from the June 13th total of 19,245,387 shares. Based on an average daily trading volume, of 2,017,510 shares, the short-interest ratio is currently 8.9 days. Currently, 30.2% of the shares of the stock are short sold.

Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Monday, April 28th. The company reported $1.40 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter last year, the company posted $0.76 earnings per share. Questcor Pharmaceuticals’s revenue was up 68.1% compared to the same quarter last year. On average, analysts predict that Questcor Pharmaceuticals will post $6.89 earnings per share for the current fiscal year.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.